On this page
Krabbe disease
This condition affects the myelin sheath, which insulates nerve cells, causing a range of neurological problems. It primarily affects infants, but later-onset forms exist, impacting movement, feeding, and development.
Available at Jeen Health
Clinical tests that include this
Overview
Krabbe disease, also known as globoid cell leukodystrophy, is a severe, rare inherited condition that damages the nervous system [PMID:33678077]. It belongs to a group of disorders called lysosomal storage diseases. In Krabbe disease, a specific enzyme, galactosylceramidase (GALC), is deficient or absent. This enzyme is essential for breaking down certain fatty substances (galactolipids) in the body, particularly in the brain and nervous system [PMID:33678077].
When the GALC enzyme is not working correctly, these fatty substances, especially one called psychosine, build up to toxic levels. This accumulation damages the myelin sheath, which is the protective covering around nerve fibres in the brain and throughout the body [PMID:33678077]. Myelin is crucial for fast and efficient nerve signal transmission. Damage to myelin, known as demyelination, disrupts communication between nerve cells, leading to the progressive neurological symptoms seen in Krabbe disease.
The most common and severe form of Krabbe disease begins in infancy, typically before six months of age. There are also less common forms that manifest later in childhood, adolescence, or even adulthood, with a broader range of symptoms and slower progression. The exact prevalence of Krabbe disease is not well established, but it is estimated to affect around 1 in 100,000 live births.
Symptoms & clinical features
The symptoms of Krabbe disease vary depending on the age of onset, but they generally involve progressive deterioration of neurological functions. In the most common infantile form, symptoms typically appear between three and six months of age. Early signs can include increased irritability, feeding difficulties, stiffness in limbs (spasticity), unexplained fevers, and sensitivity to loud noises [PMID:33678077]. Babies may also show a decline in developmental milestones they had previously achieved.
As the disease progresses, infants often experience worsening muscle weakness, difficulty swallowing, seizures, and severe developmental regression. Vision and hearing can also be affected. Over time, children with infantile Krabbe disease typically lose the ability to move, see, and respond to their environment. This form is very aggressive and quickly leads to severe neurological impairment.
Later-onset forms of Krabbe disease, which can begin from childhood to adulthood, have a more variable and often slower progression. Symptoms might include muscle weakness, difficulty walking (gait disturbances), changes in sensation, vision problems, and a decline in cognitive abilities. The specific symptoms and their severity can differ significantly among individuals with later-onset forms, making diagnosis more challenging.
Video: Genetics 101
Affected organs
Krabbe disease primarily affects the nervous system, including both the central nervous system (brain and spinal cord) and the peripheral nervous system (nerves outside the brain and spinal cord). The critical damage occurs to the myelin sheath, which is the fatty covering that insulates nerve fibres. This damage is particularly severe in the white matter of the brain.
Beyond the brain and spinal cord, the peripheral nerves are also significantly impacted, leading to nerve damage that can cause muscle weakness and sensory problems. The toxic build-up of psychosine can also affect other parts of the body, though the neurological effects are most prominent. Vision and hearing can be compromised due to damage to the optic and auditory nerves, respectively.
Risks & severity
Krabbe disease is a severe and often rapidly progressive condition, especially in its infantile form. Infants typically experience a swift decline in neurological function, with a life expectancy often limited to two to three years after symptom onset [PMID:33678077]. The severe damage to the brain and nervous system leads to profound developmental regression and loss of essential bodily functions.
For later-onset forms, the severity and progression are highly variable. Symptoms can appear in early childhood, adolescence, or even adulthood. While the progression is generally slower than the infantile form, individuals with later-onset Krabbe disease will still experience progressive neurological deterioration. The impact on life expectancy in later-onset forms can vary considerably, with some individuals living many years with significant disabilities, while others may experience a more rapid decline.
Due to its severe nature, Krabbe disease is included in some newborn screening programmes in various regions, though this is not uniform across the UK. Early diagnosis, particularly for the infantile form, is crucial for considering potential interventions, such as haematopoietic stem cell transplantation, which may slow disease progression if performed before symptoms appear.
Genetic causes
Krabbe disease is caused by pathogenic variants (mutations) in the *GALC* gene. The *GALC* gene provides instructions for making an enzyme called galactosylceramidase. This enzyme is primarily found in lysosomes, which are small compartments within cells responsible for recycling waste products [PMID:33678077].
The GALC enzyme's job is to break down specific fatty substances called galactolipids, including galactosylceramide and psychosine. These galactolipids are important components of myelin. When variants in *GALC* reduce or eliminate the enzyme's activity, psychosine cannot be broken down effectively and accumulates in cells. This build-up of psychosine is highly toxic to cells that produce myelin, leading to the destruction of the myelin sheath around nerve fibres.
The specific variant in the *GALC* gene can influence the amount of residual enzyme activity, which in turn affects the age of onset and severity of Krabbe disease. Variants resulting in almost no enzyme activity typically cause the severe infantile form, while variants that allow for some residual enzyme activity may lead to later-onset, milder forms.
- GALC galactosylceramidaseThe GALC gene provides instructions for producing galactosylceramidase, an enzyme vital for the breakdown of specific fats within the nervous system.
Inheritance pattern
Krabbe disease is inherited in an autosomal recessive pattern. This means that an individual must inherit two copies of a pathogenic *GALC* variant - one from each parent - to develop the condition.
If a person inherits only one copy of a pathogenic *GALC* variant, they are considered a carrier. Carriers typically do not show any symptoms of Krabbe disease because their single working copy of the *GALC* gene produces enough enzyme for normal function. However, two carriers have a 1 in 4 (25%) chance with each pregnancy of having a child affected by Krabbe disease, a 2 in 4 (50%) chance of having a child who is a carrier, and a 1 in 4 (25%) chance of having a child who is neither affected nor a carrier.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
Diagnosis of Krabbe disease typically begins with a clinical evaluation based on a person's symptoms and neurological examination. Blood tests to measure GALC enzyme activity are often the first step in confirming a suspected diagnosis. A significantly reduced or absent GALC enzyme activity level strongly suggests Krabbe disease [PMID:33678077].
Genetic testing is used to confirm the diagnosis by identifying pathogenic variants in the *GALC* gene. This genetic confirmation is important for definitive diagnosis, genetic counselling, and distinguishing between different forms of the disease. In the UK, individuals suspected of having Krabbe disease may be referred to a clinical genetics service by their GP or specialist for assessment and consideration of genetic testing. Genetic testing for Krabbe disease would fall under the NHS Genomic Medicine Service, typically accessed via an R-code, such as R301 'Early-onset leukodystrophy'.
Some regions also include Krabbe disease in newborn screening programmes, which can detect low GALC enzyme activity at birth before symptoms appear. This early detection is critical as it allows for timely intervention consideration, such as stem cell transplantation, which may be more effective if performed before the onset of symptoms.
Management & lifestyle
Currently, there is no cure for Krabbe disease, and management focuses on supportive care to manage symptoms and improve quality of life. For the infantile form, treatment options are limited once symptoms have appeared. However, for individuals diagnosed through newborn screening or those with later-onset forms who are pre-symptomatic, haematopoietic stem cell transplantation (HSCT) may be considered [PMID:33678077]. HSCT involves replacing the affected blood-forming cells with healthy cells from a donor, which can then produce the missing GALC enzyme. This intervention aims to slow the progression of the disease, particularly if performed before the onset of symptoms, but it is a complex procedure with significant risks.
Supportive care for symptomatic individuals involves a multidisciplinary team, including neurologists, physiotherapists, occupational therapists, speech and language therapists, and dieticians. Management may include medications to control seizures, muscle spasms, and irritability. Nutritional support, often through a feeding tube, is crucial for those with swallowing difficulties. Regular monitoring for complications such as respiratory infections is also important.
Families affected by Krabbe disease should be supported by specialist rare disease centres and receive genetic counselling. Genetic counsellors can provide information about the condition, inheritance patterns, and discuss reproductive options for future pregnancies. The NHS offers comprehensive care pathways for rare neurological conditions, guiding patients and families through diagnosis, management, and support services.
UK care pathway
In the UK, individuals with suspected Krabbe disease typically enter the NHS Genomic Medicine Service pathway. This often begins with a referral from a general practitioner (GP) or a specialist, such as a paediatrician or neurologist, to a regional clinical genetics service. Clinical geneticists and genetic counsellors are key in guiding families through the diagnostic process, including genetic testing which is carried out under specific NHS R-codes (e.g., R301 for early-onset leukodystrophy).
Upon diagnosis, patients are often managed by a multidisciplinary team within specialist centres, particularly for rare neurological conditions. These teams can coordinate ongoing care, symptom management, and access to supportive therapies. Genetic counsellors play an ongoing role, providing essential information and emotional support to families, discussing the implications of the diagnosis, and exploring options for family planning.
Frequently asked questions
What is the life expectancy for someone with Krabbe disease?
For the most common infantile form of Krabbe disease, life expectancy is typically very short, often only two to three years after symptoms begin, due to rapid neurological deterioration. For later-onset forms, the progression is slower and more variable, meaning individuals may live many years, though they will experience progressive neurological decline.
Can Krabbe disease be detected before birth?
Yes, Krabbe disease can be detected before birth through prenatal genetic testing if there is a known family history of the condition. This involves analysing DNA from cells obtained via chorionic villus sampling (CVS) or amniocentesis to look for pathogenic *GALC* variants.
Is there a cure for Krabbe disease?
Currently, there is no cure for Krabbe disease. However, for individuals diagnosed before symptoms appear (e.g., through newborn screening) or with milder, later-onset forms, haematopoietic stem cell transplantation (HSCT) may be considered to slow disease progression. For those with symptoms, treatment focuses on supportive care to manage symptoms and improve quality of life.
How common is Krabbe disease?
Krabbe disease is a rare condition. While exact prevalence figures can vary, it is estimated to affect approximately 1 in 100,000 live births. It is more common in certain populations where founder effects increase the likelihood of specific genetic variants.
If I am a carrier of Krabbe disease, will I develop symptoms?
No, if you are a carrier of a *GALC* gene variant, you typically will not develop symptoms of Krabbe disease. Carriers have one functional copy of the gene, which is usually sufficient to produce enough GALC enzyme for normal bodily functions. Symptoms only occur if you inherit two pathogenic variants, one from each parent.
References
- Jain M, De Jesus O. Krabbe Disease. 2023. PMID: 32965986
- Ferreira CR, Gahl WA. Lysosomal storage diseases. Translational science of rare diseases. 2017. PMID: 29152458
- Rafi MA. Krabbe disease: A personal perspective and hypothesis. BioImpacts : BI. 2022. PMID: 35087711
- Aisenberg WH, O'Brien CA, Sangster M. Direct microglia replacement reveals pathologic and therapeutic contributions of brain macrophages to a monogenic neurological disease. Immunity. 2025. PMID: 40311614
- Verkhratsky A, Niu J, Yi C. Neuroglial Pathophysiology of Leukodystrophies. Advances in neurobiology. 2025. PMID: 40500501
- Ghabash G, Wilkes J, Barney BJ. Hospitalization Burden and Incidence of Krabbe Disease. Journal of child neurology. 2022. PMID: 34670440
- Powers JM, Rubio A. Selected leukodystrophies. Seminars in pediatric neurology. 1995. PMID: 9422247
- Wenger DA, Luzi P, Rafi MA. Advances in the Diagnosis and Treatment of Krabbe Disease. International journal of neonatal screening. 2021. PMID: 34449528